Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
SEEGENE
AB Sciex

Urine Culture Updates Approach to Diagnosing Infection

By Labmedica International staff writers
Posted on 05 Dec 2013
Image: Flash and Grow Automatic Colony Counter (Photo courtesy of Rapidmicrobiology).
Image: Flash and Grow Automatic Colony Counter (Photo courtesy of Rapidmicrobiology).
The cause of acute uncomplicated cystitis is determined based on cultures of voided midstream urine, but few data guide the interpretation of such results, especially when gram-positive bacteria grow.

Interpreting a midstream urine culture is complicated by the potential for the specimen to become contaminated by microorganisms in the periurethra, making it difficult to distinguish whether the bacteria originated in the bladder or the periurethra.

Scientists at the Miller School of Medicine (University of Miami; FL, USA) collected midstream urine samples and catheter-derived urine from 202 women who presented with urinary tract infections (UTI) symptoms. The goal was to compare microbial species and colony counts from both samples, with the catheter urine used as the reference. Women were eligible if they were between the ages of 18 and 49 years, were in good general health, and had had typical symptoms of cystitis, dysuria and urinary frequency or urgency for seven days or less.

In catheter urine cultures, all microorganisms were fully identified and quantified to 10 colony forming units (CFU)/mL. In midstream urine cultures, all uropathogens, gram-negative rods, enterococci, group B streptococci, and Staphylococcus saprophyticus, were identified and quantified to 10 CFU/mL. Pyuria was defined as eight or more leukocytes/cu mm. The scientists found that found that even at very low counts of 102 CFU/mL, the presence of Escherichia coli in midstream urine had a high rate of predicting the presence of bacteriuria in the bladder. In contrast, the presence of enterococci and group B streptococci in midstream urine was not predictive of bladder bacteriuria in any amount.

Many commercial laboratories routinely report growth only for counts of 104 CFU/mL, cultures with lower E. coli counts may be falsely reported as negative. Conversely, midstream urine cultures often reveal enterococci and group B streptococci in amounts of 104 CFU/mL or higher, but these organisms appear to rarely cause cystitis in young women.

Thomas M. Hooton, MD, the lead author and a professor of medicine, said, “The study results reinforce the opinion of many that the voided urine culture for diagnosis of cystitis has limited value. If, however, clinicians use a voided urine culture in evaluating a symptomatic patient, the laboratory should be asked to quantify gram-negative bacteria, especially E. coli, down to 102 CFU/mL, and that low counts, even when in mixed growth with other organisms, should not be ignored. The study was published on November 14, 2013, in the New England Journal of Medicine.

Related Links:

Miller School of Medicine




GREINER-BIO-ONE
ADVANCED INSTRUMENTS
PURITAN MEDICAL
BioConferenceLive

Channels

Genetic Tests

view channel

Testing for Atypical Hemolytic Uremic Syndrome Goes NexGen

A patent pending genomic technique that rapidly sequences 12 genes associated with complement-mediated atypical hemolytic uremic syndrome (aHUS) is now being used to diagnose this rare disorder. Atypical hemolytic uremic syndrome (aHUS) is a very rare, life-threatening, progressive disease that frequently has a genetic component.... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Roche Acquires IQuum, Strengthens Diagnostics Offerings with Unique System

The acquisition by Roche (Basel, Switzerland) of IQuum, Inc. (Marlborough, MA, USA) will enable Roche to more quickly enter the point-of-care (POC) segment of molecular diagnostics with products based on IQuum proprietary lab-in-tube technology. The technology underlies a novel biological sample testing platform that enables... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.